Quantcast
Channel: Italy Headlines on One News Page [United States]
Viewing all 40166 articles
Browse latest View live

Neovacs to present clinical development update on IFNalpha Kinoid in dermatomyosis

0
0
*PRESS RELEASE* *·* *PRESS RELEASE* *·* *PRESS RELEASE*

*NEOVACS TO PRESENT CLINICAL DEVELOPMENT UPDATE ON IFNalpha KINOID IN DERMATOMYOSIS*

*At the 2nd Global Conference on Myositis*
*May 5-8, 2017 - in Potomac, USA*

* *
*Paris and Boston, May 4, 2017 - 8:00 AM CET - Neovacs (Alternext Paris: ALNEV),* a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that *Thérèse Croughs, M.D., Chief Medical Officer of Neovacs,* will present an update on the clinical development of the Company's IFNalpha Kinoid in dermatomyositis at the 2 ^nd World Conference on Myositis, to be held May 5-8, 2017, in Potomac, Maryland, USA.

*Dr. Thérèse Croughs* will present a poster titled: " *Overexpression of IFNalpha and Derived Diseases: Innovative Approach with a Kinoid IFNalpha Therapeutic Vaccine* " * on Sunday, May 7 ^th , from 10.35 am to 1.30 pm ET. * This presentation will outline the way Neovacs is developing its IFNalpha Kinoid therapeutic vaccine, in order to treat the overexpression of IFNalpha in dermatomyositis.

Neovacs' Phase IIa clinical study in dermatomyositis is currently ongoing. This multicentric study includes 30 adult patients in Europe (France, Italy, Germany and Switzerland) and aims to evaluate the immunogenicity, tolerance and biological and clinical efficacy of IFNalpha Kinoid. The results of this study, will provide data to support the design and execution of a pivotal study.

*Miguel Sieler, Chief Executive Officer of Neovacs* , said: "Based on the data generated to date, we believe our IFNalpha Kinoid has significant potential in multiple indications, including dermatomyositis.  We are excited to provide an update on this program at this leading international scientific conference.  In addition, we look forward to the availability of data from our ongoing Phase IIa clinical trial of IFNalpha Kinoid in dermatomyositis. "

*About th* e * 2 ^nd International Conference on Myositis *
Created by Dr. Ingrid Lundberg to facilitate interdisciplinary collaborations in research and accelerate the development of new clinical options, care and therapeutic modalities related to myositis, the first edition of the International Congress on Myositis was held in May 2015 in Stockholm. This second Global Conference on Myositis (GCOM 2017) is continuing this innovative series of international meetings aimed at bringing together all the world-renowned scientists and clinicians, creating connections and sharing knowledge. For more information: http://www.gcom-int.com/home.html

*About Neovacs Technology*

Neovacs targets pathologies associated with an overproduction of endogenous cytokines. This technology is based on active immunotherapy to generate an immune response through the administration of an immunogenic complex involving the target cytokine to a carrier protein. The intramuscular injection of this Kinoid induces an immune response and stimulates the production of polyclonal antibodies against the target cytokines. It is thus possible to block cytokine overproduction and its pharmacological effects. Several autoimmune and inflammatory diseases (lupus, dermatomyositis, Type 1 diabetes ...) are characterized by a disorder of cytokines that are found produced in excess (ex: IFNalpha). This overproduction will promote inflammation and dysregulation of the immune system.

*About* *Dermatomyositis*
Dermatomyositis (DM) is a rare, autoimmune and inflammatory disease characterized by severe skin lesions and muscle weakness with varying impact on physical abilities. Other systems may also be impacted (vascular, pulmonary, gastrointestinal and cardiac). One in three adult patients with DM develops cancer within three years of the first manifestations of the disease. The DM affects mostly children. It is twice more common in women than in men. No biological treatment has so far been authorized in this indication. The prevalence of DM is between one case per 50 000 and one case per 10 000, conferring orphan disease status in Europe and the United States ^[1] .
 Neovacs thus estimates that IFNalpha-Kinoid could benefit from accelerated clinical development in DM due to the status of an orphan condition of this disease, allowing a market access in the next few years.*About Neovacs*
Listed on Alternext Paris since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNalpha-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology, allergies and Type 1 diabetes. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

*Contacts*
*                                                              *
*NEOVACS - Corporate Communication & Investor Relations*
*Charlène Masson*
+33 (0)1 53 10 93 14
cmasson@neovacs.com

*LIFESCI ADVISORS- Investor Relations / Financial Communications*
*Chris Maggos*
+41 79 367 6254
chris@lifesciadvisors.com
--------------------

^[1] www.orpha.net

english pdf
--------------------This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: NEOVACS via GlobeNewswire

HUG#2101587 Reported by GlobeNewswire 46 minutes ago.

2 Italian riders nabbed for doping on eve of Giro d'Italia

0
0
ALGHERO, Italy (AP) Two riders from the Italian team Bardiani CSF have been kicked out of the Giro d'Italia on the eve of their nation's biggest race after testing positive in an out-of-competition doping test. Reported by FOX Sports 11 hours ago.

Europe's Inaction Is Bad News For The Mental Health Of Refugees And Migrants

0
0
Tens of thousands of refugees and migrants continue to languish in camps and informal settlements across Europe, waiting for word on what their next move will be. The uncertainty these predicaments create are placing even more weight atop already fragile mental states, those working with them on the ground say.

“Nearly 75,000 refugees and migrants, including an estimated 24,600 children, currently stranded in Greece, Bulgaria, Hungary and the Western Balkans are at risk of psychosocial distress caused by living in a protracted state of limbo,” UNICEF warned Thursday in a press release.

It’s impossible for most refugees to know what the next step of their journey will entail ― and that causes serious stress. Depression and anxiety are commonplace. 

“They don’t know if they’re staying in a [refugee] camp for two weeks or two years,” said Andres Barkil-Oteo, a psychiatrist with Doctors Without Borders (also known as MSF). “This prevents people from actually adjusting and accommodating to their new environment.”

Luckily, a little bit of psychosocial support goes a long way. Basic mental health interventions have led to significant improvements among people stuck in places like Greece, experts said.Refugees and migrants can only access Europe via two primary points of entry ― from Turkey to Greece via the Aegean Sea, or from Libya to southern Italy via the central Mediterranean.

Many European countries have sealed off their borders to stem the influx of people. It means that people end up stuck in places like Greece and Serbia for indefinite periods of time, even though most hoped to head west toward countries with favorable asylum policies, like Germany and Sweden.

Greece has been hit especially hard since it’s a first point of entry. There are currently about 47,000 refugees and migrants in Greece, according to statistics from the U.N. refugee agency.Organizations like UNICEF and MSF have been on the ground in these countries for many months. Psychosocial support is a core tenet of their work with refugee and migrant populations.

UNICEF said emotional distress is particularly acute among single mothers and children, who are often are awaiting to reunite with family members in other EU countries.

“Many single mothers are feeling stuck and seem to have lost motivation,” said Sofia Tzelepi, a lawyer working with UNICEF partner Solidarity Now. “Their emotional state affects their children.”

UNICEF provides basic psychosocial support to children across Greece’s mainland in the form of safe spaces, education and recreation. 

“We know that for the majority this is going to be sufficient to recover and carry on,” said Laurent Chapuis, UNICEF’s Greece coordinator for the refugee and migrant response. “But this is also the way for us to identify the kids that are going to require extra help.”

Fortunately, only about 15 to 20 percent of the children they work with end up needing individualized psychological treatment, he added.
MSF offers three tiers of mental health support, Barkil-Oteo said. For those who need help coping with stress, psycho-educational campaigns have been created to inform people about their symptoms and about the arduous asylum process they are in the thick of. 

Barkil-Oteo also helped lead more specialized group intervention exercises during his six months in Greece, he explained. They would discuss topics like stress or domestic violence.

“A lot of people don’t feel comfortable coming to us to do an individual session but require some type of support,” he said about the rationale behind group sessions. “You foster a place where people can help each other.”

MSF also provides traditional mental health services, including individual sessions with psychologists and medical consultations with psychiatrists like Barkil-Oteo. 

But echoing Chapuis, he said these cases are the exceptions. Only about 20 to 25 percent of people required this kind of targeted intervention, he noted. Most are able to bounce back naturally with proper psychosocial support.

“People tend to be generally resilient and dynamic,” he said. “Many of them are actually doing really well and are even trying to help others.”

*Want to help? Donate to organizations like UNICEF, MSF, the International Rescue Committee and UNHCR that are working day in and day out to help migrants & refugees in places like Greece, Serbia and Bulgaria.*

-- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. Reported by Huffington Post 11 hours ago.

Trump And Pope Francis Will Finally Meet After A Year Of Ideological Sparring

0
0
Pope Francis will receive President Donald Trump at the Vatican on May 24 in what could be an uncomfortable meeting given the world leaders’ history of antagonism toward one another.

Trump will make his first trip abroad as president this month, with stops in Saudi Arabia, Israel, Italy and Belgium. The president will arrive in Rome after visiting the Middle East in an attempt to highlight his promises to defeat the self-fashioned Islamic State and bring peace between Israel and the Palestinians.

From Rome, Trump will travel to Brussels for a NATO summit and then to Sicily for a meeting of the Group of Seven economic powers.

As of April, the White House had not approached the Holy See for an audience with the pope during Trump’s trip. But on Thursday the Vatican confirmed that the leaders would be meeting at 8:30 a.m. on Wednesday, May 24 in the Apostolic Palace.

It’s an unusual day and a strangely early time for a head of state to meet the pope, Reuters noted. The pontiff typically holds a weekly general audience on Wednesday mornings, and senior Vatican sources told Reuters the meeting with the president had to be squeezed in before that.

It seems Trump had to squeeze meeting the pope into his schedule, too. Over the weekend the pope told reporters aboard the plane returning from a trip to Egypt that he wasn’t aware of any request from Trump for a meeting. He reiterated the policy that a pope meets with any head of state who asks for a private audience.President Obama met Pope Francis twice ― once at the Vatican in 2014 and also during the pontiff’s trip to the United States in 2015. Obama also met with Francis’s predecessor, Pope Benedict XVI, at the Vatican in 2009.

If there’s reluctance on either Trump’s or Francis’s side for the meeting, it wouldn’t be surprising. The pair hold diametrically opposing views on a number of key issues, including immigration policy and climate change. During Trump’s campaign for president, the pontiff criticized the Republican candidate’s plan to build a wall along the U.S.-Mexico border. Speaking aboard his papal plane in February of last year, the pope was asked about Trump’s proposal. He told reporters: “A person who only thinks about building walls, wherever they may be, and not building bridges, is not Christian.” Francis stressed that he wasn’t trying to tell Americans how to vote. “I am not going to get involved in that,” he said. But he added: “I would only say that this man is not Christian if he has said things like that.”

Trump posted a long response on his personal Facebook page later that day in an attempt to intimidate the Catholic leader. “If and when the Vatican is attacked by ISIS, which as everyone knows is ISIS’s ultimate trophy, I can promise you that the Pope would have only wished and prayed that Donald Trump would have been President because this would not have happened,” he wrote.

The pope has been less pointed in his comments since Trump’s inauguration, but relations between the two have hardly warmed.

In his first official telegram to Trump in January, Francis said: “Under your leadership, may America’s stature continue to be measured above all by its concern for the poor, the outcast and those in need.”

-- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. Reported by Huffington Post 9 hours ago.

David Burtka Reveals Couples Therapy Helped His Relationship With Neil Patrick Harris — And These Other Celeb Couples Would Agree!

0
0
Almost every marriage needs maintenance over the years, and husbands Neil Patrick Harris and David Burtka are no exception! Though the couple wed in Italy in 2014, they've been together for 13 years — and David admitted the trick to making his relationship with the Series of Unfortunate Events star work is couples therapy! Speaking to Life [...] Reported by Perez Hilton 9 hours ago.

Google pays Italy taxes; Lyft and leather; ‘Halo’ to Hall of Fame

0
0
Google pays Italy taxes; Lyft and leather; ‘Halo’ to Hall of Fame U.S. multinational corporations now hold an estimated $2.6 trillion overseas, most of it from tech companies’ global operations. People for the Ethical Treatment of Animals said in a blog post that the San Francisco ride-hailing company has changed its leather-only requirement in Lyft Premier vehicles to allow for vegan leather. PETA says it takes an average of three cows’ hides for the interior of a standard car, adding that many luxury automakers use vegan leathers. Combat Evolved, a science fiction shooter game that enthralled a legion of fans after its 2001 release with the Xbox system, has made it into the World Video Game Hall of Fame. All will be on permanent display at the Strong museum in Rochester, N.Y., where the hall was established in 2015 to recognize an industry that the Entertainment Software Association said generated $30.4 billion in revenue in the U.S. last year. Reported by SFGate 8 hours ago.

Italian Prime Minister Secretly Meets With George Soros In Rome Amid Migrant Transport Scandal

0
0
Italian Prime Minister Secretly Meets With George Soros In Rome Amid Migrant Transport Scandal Submitted by Gefira

In the past few weeks, the transport of migrants from the African shores has become a case of national importance for Italy, and is now under investigation from the prosecutor of Catania, who recently testified to the Defence Committee of the Italian Senate and will meet soon with the Superior Council of the Magistrates.

Harsh criticism of the activities of the NGOs has come from opposition parties Forza Italia, Lega Nord and even Movimento 5 Stelle, normally more neutral on immigration issues, while Prime Minister Gentiloni has opted to let the judicial system run its course.

Yet, a new element will further exacerbate the situation; George Soros, a billionaire who is incredibly active politically on both sides of the Atlantic, met in secrecy with Prime Minister Gentiloni, less than a week after the latter had commented on the NGOs activities. The meeting was not listed on the website of the Italian government as official and its timing is at the very least suspicious.

George Soros had penned multiple arguments in favour of immigration, suggesting that Europe should welcome “at least one million refugees a year” and that the EU should create EU-bonds to support attendant expenses.

He’s no stranger to NGOs either: one of them, MOAS (Migrant Offshore Aid Station), facing the harshest criticism , received half a million dollars from Avaaz, another NGO, co-founded by MoveOn, an online community, receiving donations from none other than George Soros himself.

Save The Children, another NGO involved in the Mediterranean migrant shipping, lists among its partners Open Society Foundation, George Soros’s primary NGO. Finally, even, Médicins Sans Frontiéres is listed among the partners of Open Society and the Soros network.

Soros had already been named by Lega Nord leader Salvini as the secret financier behind the NGOs and his well-timed arrival is bound to create further controversy.
No information has been leaked so far about the content of the meeting between Soros and Gentiloni.

Is the cat out of the bag? Reported by Zero Hedge 3 hours ago.

Italian Prosecutor Investigating NGO Rescuers Says Has No Proof Of Wrongdoing

0
0
(EurActiv) — An Italian prosecutor who began an investigation into possible ties between humanitarian organisations that rescue migrants at sea and Libya-based people smugglers said on Wednesday (3 May) he had no proof of any wrongdoing.

Carmelo Zuccaro, the chief prosecutor of the Sicilian port city of Catania, previously said he had evidence of phone calls between people smugglers and aid groups, but on Wednesday he said he was expressing only a “hypothesis” and had no proof that could be used in court.

“The ample amount of money that some of the newer NGOs have is an element of suspicion and it is something we are looking into … No evidence has yet been found” of illicit funding, Zuccaro said. “The profiles of some NGO crew members are not exactly philanthropic.”

Speaking before a parliamentary committee convened to investigate his claims, which he first aired in February when he announced the fact-finding inquiry, Zuccaro asked lawmakers to provide more resources and suggested putting police on ships in the rescue zone.

Without more resources, his office is not able to further the investigation, he said. Information he had collected so far about the activity of non-governmental organisation ships came from the EU border agency Frontex, Italy’s navy and coast guard, and the Internet, he said.

Various NGOs have strongly denied all allegations they have colluded with people-smugglers.

Zuccaro has become a divisive figure in Italy’s increasingly heated debate about immigration, which is likely to become a key issue in the national election due by next May. Italy has been left virtually alone to manage hundreds of thousands of migrants who have come by boat from North Africa. More than 1,000 migrants have died this year attempting the passage.

Migrant arrivals are up 30 percent so far this year from 2016 when a record 181,000 came by boat. Because they are no longer moving onto Northern Europe as they did previously, their presence is now more visible in cities and towns across the country.

Border closures by Italy’s European Union partners and more strict identification procedures mean that more of the migrants are choosing to seek asylum in Italy.

Last week, Justice Minister Andrea Orlando said it was “a lie” to paint aid groups as criminals and urged Zuccaro to open a criminal investigation if he had proof of wrongdoing. No such investigation has been opened.

On the other hand, the leaders of the 5 Star Movement, currently polling as the country’s most-popular party, and the anti-immigrant Northern League condemned non-governmental groups for providing a “taxi” service to migrants.

“Our country is not able to take in all migrants — including the economic migrants,” Zuccaro said, referring to those who do not qualify for asylum. Reported by Eurasia Review 4 hours ago.

Google agrees to pay 306 million euro to end Italy tax deal

0
0
Internet giant Google agreed to pay 306 million euros to end a tax dispute in Italy, the company and the country’s tax authority announced. The amount covers the period between 2002 and 2015 and refers to Google Italy and Google Ireland, Google and Italy’s tax agency said. Google’s parent company Alphabet, whose motto is ‘Do the Right Thing’, has been probed in Italy and other countries for booking income in Ireland, where taxes are lower. Italy’s tax agency said talks would begin on signing “preventive agreements” to ensure the company pays the correct tax in the future. The US-based company has previously said it complied with tax rules in all the countries it operates in. It has defended the legality of funnelling its European earnings through its base in Ireland, which has one of the lowest Reported by BGR India 3 hours ago.

France, vote for Macron! Like him or not, he gives hope for the future

0
0
France, vote for Macron! Like him or not, he gives hope for the future My intellectual French friends said: “Mon dieu. We couldn’t watch the debate. The mud-slinging. The interruptions. I couldn’t bear it.”

Being neither intellectual nor French, I loved the TV debate on Wednesday night between presidential rivals Emmanuel Macron and Marine Le Pen. It was riveting, engaging and fulfilled its purpose of showing two radically different candidates with two radically different visions for France.

Centrist Macron kept his cool, and was poised and prepared throughout the two and a half hours. His ideas were clear, well thought-out and his demeanour was presidential. Marine Le Pen was also engaging at times, but lost credibility by confusing French companies (Macron explained to her the firm she was talking about made trains and not phones), a fatal error that she never quite recovered from. Her thinking on the euro (with the strange idea of creating a parallel local currency to use only inside France) was muddled and confused – and we’re none the wiser about what she actually wants France’s relationship with the single currency to be.

*Read more*: Apres Macron, le deluge: European elites’ last chance to avert disaster

She spent too much time making personal attacks on Macron, on his proximity to big business and big finance (he was formerly a banker at Rothschild) and not enough talking about policies. Her tactic was to constantly make jibes at Macron, using innuendo and accusation in an attempt to make him lose his cool. He didn’t lose his cool.

Macron’s campaign pledges include closer regional integration, corporate tax cuts and labour reforms. He also advocates cuts to payroll taxes and a higher employment bonus for low-paid workers.

The only time that Macron was less than convincing was on terrorism. Madame Le Pen said he would be weak in dealing with jihadi terrorists, and Monsieur Macron mentioned that a lot of terrorists were French and so the country should examine its own conscience for letting it happen. He may not be wrong, but his argument may not go down well with French voters. Other than that, he was impressive.

The latest poll said front-runner Macron did better than his opponent in the debate, with 63 per cent of viewers thinking he was stronger – mirroring broader polling of voting intention for the second round on Sunday.

*Read more*: Timid centrist Emmanuel Macron is unlikely to fix a failing France

Markets like that poll, and they like the idea of Macron as President – not because “President M” will look after his friends (as Le Pen suggested) but because the spectre of populism and protectionism will have been pushed away (for now). He’s also a politician that represents hope for the future, with a clearly laid-out vision for the French Republic that is open, strong and confident. It’s no wonder he’s a popular candidate with the young. He made a positive argument for Europe and a positive argument for keeping open borders.

One of my favourite tweets of debate night was from film director Hugo Gelin: “Le Pen is talking about Macron. Macron is talking about France.” Most of the other tweets were focused on the poor two moderators, who couldn’t get in a word edgeways.

But there are still risks. Let’s remember about 40 per cent of the French voted for extreme parties (on the left or right) in the first round of the presidential elections. And people still need to go and vote. Turnout is key. The fewer people vote, the higher Le Pen’s share is likely to be. And the margin by which Macron wins (assuming he wins, but we should never assume) could be influential in the legislative elections in June. With no majority, his hands will be tied, and populism and protectionism could really take hold in France in five years.

*Read more*: Hold the champagne: Why Emmanuel Macron will struggle to fix France

I worry that if the charismatic centrist candidate can’t deliver on his promises for reform and growth, the French will become disillusioned, like in Italy. I worry that down the line Macron will become a casualty, just like former Italian Prime Minister Matteo Renzi. So this is not the time to be complacent. Macron needs a strong majority so he has a chance of getting things done. Without support, he’ll be a lame duck President.

If you’re French, *please go and vote*, for everyone’s sake.

These views are not necessarily shared by Bloomberg. Reported by City A.M. 4 hours ago.

Italy in European Competition — Can Juventus Hoist the Trophy?

0
0
Can Juventus win the Champions League? It sure looks like it. They demolished Monaco 2-0 in France, and they knocked out Barcelona on their way to getting here. What would a win mean for the Serie A as a whole? Bragging Rights For the first time since 2010, an Italian team could win the Champions […] Reported by SoccerNews.com 4 hours ago.

Myanmar: Ruling Party Mulls Legal Action Over Rumor About President’s Resignation

0
0
Myanmar’s ruling National League for Democracy party may take legal action against individuals or the group responsible for posting online rumors that the country’s figurehead president is resigning, the party’s spokesman said Thursday, in the latest indication of a clampdown on free speech in the Southeast Asian nation.

Recent posts on Facebook indicated that President Htin Kyaw would step down due to poor health and be replaced by Shwe Mann, the former speaker of the lower house of parliament who is close to State Counselor Aung San Suu Kyi—the country’s de facto leader.

NLD spokesman Win Htein said action will be taken against those who are “spreading rumors” that the country’s President Htin Kyaw is being replaced.

“As far as I’m concerned, this was done by people who are trying to politically destabilize the country while Daw [honorific] Aung San Suu Kyi is away,” he said, referring to the state counselor’s current official visit to Europe, where she was in Italy on Thursday.

“I called Home Affairs Minister Lieutenant General Kyaw Swe yesterday to tell him to find the person responsible for the original post and take legal action against him,” Win Htein said. “We will find out whether it is an individual or an organized group, and I might file a lawsuit against them, or I will ask someone else to do that.”

The NLD’s central executive committee will discuss whether or not to file a lawsuit against those responsible for the post at the body’s next meeting, he said.

In the meantime, the State Counselor’s Office urged the public to disregard the rumor.

Htin Kyaw is serving as a proxy for Aung San Suu Kyi, who is constitutionally barred from the presidency because her sons are foreign-born as was her late husband.

*‘Leaking state secrets’*

In a related development, Myanmar’s Ministry of Industry said on Thursday it will sue a U.S.-based Facebook blogger for posting what it called a rumor.

Aung N Htwe wrote that former Major Ko Ko Aung asked Khin Maung Cho, the current industry minister, to transfer about 20 officials in positions above that of Ko Ko Aung, and that the minister agreed.

Aung N Htwe included photos of the minister and his wife along with his Facebook post.

In response, the ministry issued a statement that it will investigate those involved and take action against them for “leaking state secrets.”

“We transferred 22 staff due to job needs,” said Ko Ko Lwin, the ministry’s permanent secretary. “There is no other reason for it. People can accuse us of what they want to online, [but] we need to check these rumors and respond as needed according to law.”

*Revision of Article 66 (d)*

Also on Thursday, Nu Nu Yin, permanent secretary of the country’s Attorney General’s Office, said during a press conference reviewing the NLD government’s accomplishments during its first year in office that controversial Article 66 (d) of the Telecommunications Law will be revised.

The article prohibits use of the telecom network to “extort, threaten, obstruct, defame, disturb, inappropriately influence or intimidate” people and carries a jail sentence of up to three years and a fine for those who violate it.

“We were advised that we should consider bailing out people charged under Article 66 (d),” Nu Nu Yin said, responding to a question about a request her agency received from the Ministry of Communication to amend the article.

Some rights groups have criticized Aung San Suu Kyi, widely touted as a democracy icon in the West, for failing to live up to expectations for increased freedom of the press under the NLD administration.

The number of defamation suits filed under Article 66 (d) have soared under Aung San Suu Kyi’s administration, with 56 people charged for social media posts deemed inappropriate—12 of whom were journalists.

During the previous military-backed government of former president Thein Sein, only seven people were charged under Article 66(d), five of whom received prison sentences.

Reported by Win Ko Ko Latt, Thet Su Aung and Win Naung Toe for RFA’s Myanmar Service. Translated by Khet Mar. Written in English by Roseanne Gerin. Reported by Eurasia Review 4 hours ago.

ET Energy Commissions 26 MWp of Solar Projects in the UK

0
0
NANJING, China, May 5, 2017 /PRNewswire/ -- ET Energy, a global leading clean energy developer and operator, announces that it has built six solar power projects totaling 26 MWp in the United Kingdom on behalf of funds managed by Octopus Energy Investments. The plants were constructed on a turnkey basis, and were all successfully completed and producing energy by March 31st, 2017, meeting the deadline to be eligible for 1.2 Renewables Obligation Certificates (ROC).ET Energy Commissions 26 MWp of Solar Projects in the UK

ET Energy acquired the development rights to these projects during 2016 and sold them to funds managed by Octopus Energy Investments at the end of the year. A turnkey EPC contract was provided by ET Solutions, a subsidiary of ET Energy. The six projects, all ground mounted PV sites, are situated in different locations across England, Wales and Scotland.

One of the project package was built on a dormant landfill site in Wales, which presented ET Energy with added design, engineering and construction challenges, but they were successfully overcome.

Dennis She, President and CEO of ET Energy, said, "With these six UK solar projects, we have demonstrated again that we are capable of delivering high quality, investment grade solar project assets. They represent another example of our execution capabilities, as well as the success of our transition into the downstream segment of the market."

Matt Setchell, head of Octopus Energy Investments, said, "The 1.2 ROC subsidy cliff made this a challenging project. As ever the March deadline placed pressure on construction timetables. Our solar experience, together with ET Energy's development and construction capabilities, proved a successful combination. We're pleased to add these projects to our continually growing clean energy activities."

*About Octopus Energy Investments*

Octopus Energy Investments is part of the Octopus Group, which seeks to improve the lives of millions of people by transforming the industries we operate in. Over the last six years Octopus Energy Investments has managed over GBP2bn of new funding for clean energy across solar, wind, gas reserve power plants, anaerobic digestion, landfill gas and biomass, predominantly located in the UK, but also in France and Italy. Octopus continues to grow this business.

*About ET Energy*

ET Energy is a global leading clean energy developer and operator. With innovative solar technologies and tailored financial solutions, ET Energy provides professional solutions across the entire solar power plant lifecycle including development, financing, engineering, procurement, construction, and operations & maintenance. To learn more about ET Energy, please visit http://www.etsolar.com.

*For more details, please contact:
*Eric Zhang
Tel: +86 25 8689 8098 ext.9011/+86 136 4518 8386
Fax: +86 25 8689 8097
E-mail: eric.zhang@etsolar.com / pr@etsolar.com

Photo - https://photos.prnasia.com/prnh/20170505/1843946-1 Reported by PR Newswire Asia 3 hours ago.

Ringmetall starts the year with substantial growth in sales and earnings

0
0
DGAP-News: Ringmetall Aktiengesellschaft / Key word(s): Quarter Results

05.05.2017 / 07:00
The issuer is solely responsible for the content of this announcement.
--------------------

- Good order situation and a rise in the steel price lead to a significant increase in sales volumes
 
- Sales revenues in the first quarter rose significantly by 19.2 percent to 26.7 million euros
 
- EBITDA increases by 7.9 percent to EUR 3.2 million

- In-house developments increase demand in the Industrial Handling division

*Munich, 5 May 2017 - Ringmetall AG (ISIN: DE0006001902)*, a leading global specialist in the packaging industry, posted significant sales and earnings growth in the first quarter. In addition to increased demand for the company's products, the sharp rise in the steel price in particular had a positive effect on the company's sales performance.

According to the figures published today on the business developmet in the first quarter of 2017, consolidated sales rose significantly by 19.2 percent to EUR 26.7 million (Q1 2016: EUR 22.4 million). Gross profit increased by 13.6 percent to EUR 11.8 million (Q1 2016: EUR 10.4 million), although the gross profit margin of 44.3 percent was lower than in the previous year (Q1 2016: 46.5 percent). This correspondingly affected all other profit margins. Earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to EUR 3.2 million, an increase of 7.9 percent compared to the previous year (Q1 2016: EUR 3.0 million), whereas earnings before interest and taxes (EBIT) of EUR 2.1 million rose slightly stronger by 9.6 percent compared to the previous year (Q1 2016: EUR 1.9 million).

'The first quarter was very successful for us', says Christoph Petri, Spokesman of the Management Board of the Ringmetall Group. 'The rise in sales was largely due to the rise in steel prices. Nevertheless, we have been able to significantly improve our earnings. This is not least a sign that we can raise more and more synergies within the Group.'

The key business performance figures for Q1 2017 are listed below:

EUR (thousands) Q1 2017 Q1 2016 Deviation
Sales revenues 26,663 22,369 19.2%
Gross profit 11,810 10,400* 13.6%
Gross profit margin 44.3% 46.5%*  
EBITDA 3,245 3,008 7.9%
EBITDA margin 12.2% 13.4%  
EBIT 2,060 1,879 9.6%
EBIT margin 7.7% 8.4%  

*The comparative figures in Q1 2016 have been adjusted in order to take account of the legal changes in the course of the Accounting Directive Implementation Act.

Steel price changes were the most pronounced effect on the core business segment of Industrial Packaging. Sales rose by 23.4 percent to EUR 22.7 million (Q1 2016: EUR 18.4 million). The steel price-related effect in sales growth was above ten percentage points. The division's EBITDA improved by 5.7 percent to EUR 3.4 million (Q1 2016: EUR 3.2 million). The German market in particular showed a positive development, where a sharp increase in demand for clamping rings was recorded. Exports to Latin America were also up significantly, where among others Cuba is now supplied with products. However, business in Turkey developed tricky. Thus as expected, sales were down compared to the previous year due to exchange rate effects.

In the Industrial Handling division, investments in self-developed products showed initial success. Accordingly, sales rose by 1.5 percent to EUR 4.0 million (Q1 2016: EUR 3.9 million). EBITDA further recovered to EUR 0.25 million, up 5.4 percent (Q1 2016: EUR 0.24 million). Demand rose particularly in the area of ​​restraint systems for forklift trucks. However, sales of subcontracting products for the agricultural machinery industry also increased. Here stabilizers and clutch systems were the main demand.

'The increased demand in the Industrial Handling Division underlines that we have made the right decision with our increased investment in new products', Christoph Petri explained. 'In addition, we have appointed Mr. Kuhlmann, a very experienced manager, as the new Managing Director of our subsidiary HSM. We therefore assume that the current positive momentum will prove sustainable.'

The Management Board of the Ringmetall Group continues to assess positively the current market environment for company acquisitions. After initial discussions and extensive market surveys, the company expects to successfully complete one or two smaller acquisitions in the current financial year. With regard to the development of the company in the full year, the Management Board adheres to the previously communicated outlook.

Further information about the Ringmetall Group and its affiliated subsidiaries is available at www.ringmetall.de.*Contact:*

Ingo Middelmenne
Investor Relations
Ringmetall AG

Phone: +49 (0)89 45 220 98 12
E-mail: middelmenne@ringmetall.de

*About Ringmetall Group*

Ringmetall is an internationally leading specialist in the packaging industry. The Industrial Packaging business segment offers highly secure gasket and locking systems for the chemical, the petrochemical and the pharmaceutical industry as well as the food industry. The Industrial Handling business segment develops application-optimized vehicle accessory parts for the handling and transport of packaging units. Besides its headquarters in Munich, Ringmetall has worldwide production and sales subsidiaries in Germany, Great Britain, Spain, Italy, Turkey, the Netherlands, as well as in China and the USA. On a global scale, Ringmetall generates revenues of more than EUR 90 million per year.
--------------------

05.05.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------

Language: English
Company: Ringmetall Aktiengesellschaft
Mannhardtstr. 6
80538 München
Germany
Phone: 089 / 45 22 098 - 0
Fax: 089 / 45 22 098 - 22
E-mail: info@ringmetall.de
Internet: www.ringmetall.de
ISIN: DE0006001902
WKN: 600190
Listed: Regulated Unofficial Market in Berlin, Tradegate Exchange; Open Market (Scale) in Frankfurt
 
End of News DGAP News Service Reported by EQS Group 2 hours ago.

NBPE: Redemption of 2017 ZDPs

0
0
THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONSNB ... Reported by FinanzNachrichten.de 59 minutes ago.

Lord Conrad's New Music Single "Touch The Sky" Is on Fire

0
0
Lord Conrad, of Massive Arts Studio in Milan, is receiving much media attention for his newly released digital single “Touch The Sky”

Rome, Italy (PRWEB) May 05, 2017

Today, Lord Conrad's new music single "Touch The Sky" is officially available in all digital stores, including iTunes, Google Play, Amazon USA, Amazon Japan and hundreds more. The single is already having an unexpected success!

Industry speculators say "Touch The Sky" could become this summer's big entry and a strong new hit on the internationals charts.

Lord Conrad is already known for his lavish lifestyle. The Italian model and singer, known also as THE AESTHETIC LEADER, is now dating a mysterious Polish model.

He describes his new single as a never done before sonorous experiment: a mix between trance and EDM electronic music. His song is lead by beats and melodic stabs of electronic piano with excellent vocal skills. Of course, the lyrics capture his lifestyle perfectly, and an enthusiastic listener stated: "this is a masterpiece of musical art." Additionally, they stated: "Lord Conrad's new music is a perfect combination of melodic and explosive sounds, the perfect combination of a two times speed new generation lifestyle!"

In a special interview, Lord declared that he wrote the song in his underwear at 3 a.m, claiming that this is when he feels most inspired.

His artistic philosophy and his song reflect his own sweet, altruistic and sensitive character.

Here is an excerpt of his philosophy taken from his personal Facebook page: "I love helping and listening to others. I think that every single person has the potential to achieve great things. I believe people should focus on spreading positive messages, and this is what my new single is about. Just be yourself and follow your passion."

Stay tuned as Lord Conrad is already working on the official music video to accompany "Touch The Sky," which will be released very soon.

Lord Conrad is a name people will soon hear a lot of because he is already considered a rising star ready to challenge the international charts.

Find more and listen to this new single on the links below:

Official Website:
http://www.lordconrad.com/

Official Facebook Announcement:
https://www.facebook.com/photo.php?fbid=10158410339090417&set=rpd.743270416&type=3&theater

YouTube Channel:
https://www.youtube.com/channel/UC6UfXd-b2VsIg8UUd3YFJMw

Lord Conrad - "Touch The Sky" new music single trailer:
https://www.youtube.com/watch?v=fmHKwLi5qaQ

Facebook Fan Page:
https://www.facebook.com/lordconradnasdaqgod

Apple Store:
https://itunes.apple.com/album/id1227943806?ls=1&app=itunes

Amazon Store:
https://www.amazon.it/Touch-The-Sky/dp/B06ZXZSFNX/ref=sr_1_1?s=mobile-apps&ie=UTF8&qid=1493590754&sr=8-1&keywords=Lord+conrad+touch+the+Sky

Google Store:
https://play.google.com/store/music/album/Lord_Conrad_Touch_The_Sky?id=Bl34l3osuhp7hnfy5px3xqaew3e

Vimeo Channel:
https://vimeo.com/lordconrad

Instagram:
https://www.instagram.com/lordconraditaly/

Blog:
https://lordconradblog.wordpress.com/ Reported by PRWeb 11 minutes ago.

CIAO BAMBOLINI - Italy for kids - Italian-American Kids’ Show Now Streaming Digitally on Amazon.com

0
0
Originally released on DVD, “Ciao Bambolini – Italy for Kids” is now available via digital streaming on Amazon. The show, created by award-winning actor Michael Tassoni, was born out of a love for Italy and desire to introduce it to his children and kids across the country.

Scottadale, Arizona (PRWEB) May 05, 2017

Originally released on DVD, “Ciao Bambolini – Italy for Kids” is now available via digital streaming on Amazon. The show, created by award-winning actor Michael Tassoni, was born out of a love for Italy and desire to introduce it to his children and kids across the country. “I looked for something that would show Italy to my kids in an entertaining way, and found nothing that could keep them watching,” said Tassoni, who also produced, directed and created the show, now streaming at Amazon.com and via ciaobambolini.com. “I decided to do it myself. I grew up speaking Italian and traveling to visit my family in Italy.”

Tassoni Media, an Arizona-based production company, announced today the launch of “Ciao Bambolini – Italy for Kids” in streaming digital format. The show features one professional actor (Tassoni) playing five different characters with the goal of teaching Italian language, music, art, food and culture in a fun, entertaining and engaging way. The show features original music and graphics.

Tassoni’s parents left a financially bereft Italy in the 1950’s for the then-thriving Venezuela and became clothing designers. In 1961 they made the move to Phoenix and built a successful business in the Biltmore Fashion Park. Tassoni was born in Phoenix 8 years later. “My parents were true artists, and they instilled a drive for success and a need for Italian culture in my life,” said Tassoni. “They spoke only Italian at home, so I learned the language through them, and through visits to our family in Naples and Abruzzo all my life.” The show is the natural culmination of Tassoni’s list of talents coming together along with his past, and his current life with his children. “My kids and my parents are the inspiration for this show. I’m glad I was able to bring such a talented team together to create it for kids all over the country to enjoy.”

The script was written by Tassoni’s wife, writer Kristine Tassoni. “I’ve been exposing my wife to the Italian culture for ten years now, so it was a natural fit for her to do the writing,” said Tassoni. “We came up with the characters, she wrote it and we started shooting.”

Characters include chef Luigi, Raphael the painter, Mario the racecar driver, Paolo the singing gondolier, and host character, Michael. Playing five characters wasn’t much of a stretch for Tassoni, who has performed in professional regional theater for years. Tassoni produced and starred in two independent, award-winning feature films and won Best Actor for one role at the San Diego Film Festival in 2008. He also performed the lead character Dimitri in 20th Century Fox’s “Anastasia.”

To view the trailer go to https://www.youtube.com/watch?v=jBZwfB8I1P4. To learn more about “Ciao Bambolini – Italy for Kids” go to http://www.ciaobambolini.com or visit Facebook.

About Michael Tassoni

Michael began his career as an actor at the age of 15. Since then, and having received a BS in Acting from Arizona State University, he became an Equity actor and performed in regional theatre. In 1995, Michael had the opportunity to work with the legendary Don Bluth on the 20th-Century Fox Feature Film “Anastasia,” for which he performed the lead role of Dimitri. In 1997 Michael produced and starred in the feature film “14 Ways to Wear Lipstick.” The film was
selected in the 1999 Slamdance Film Festival among others. Michael later produced and starred in “The Appearance of a Man,” for which he won Best Actor in the San Diego Film Festival in 2008. Michael started his own production company, Tassoni Films, in 2006. Reported by PRWeb 12 minutes ago.

Esperite (ESP), The Cell Factory demonstrate anti-inflammatory mode of action of CF-MEV-117 extracellular vesicle drug candidate for Epilepsy

0
0
*Esperite's (Euronext: ESP) biotech subsidiary The Cell Factory develops extracellular vesicles (EVs) biologic drug (CF-MEV-117) for treatment of drug-resistant epilepsy in children.* *The consortium sponsored by The Cell Factory have achieved an important milestone in the* *CF-MEV-117 drug development confirming an anti-inflammatory and immunosuppressive activity of the CF-MEV-117 in a dose response manner. Full results will be presented during the International Society for Extracellular Vesicles (ISEV) meeting in Toronto, Canada from* *18-21 May, 2017.*

Zutphen, The Netherlands - 5 May 2017

The Cell Factory, a company of Esperite Group in collaboration with Bambino Gesù Children's Hospital in Rome, Mario Negri Institute for Pharmacological Research in Milan and Women's and Children's Health Department of the University of Padua are developing the EVs drug candidate (CF-MEV-117) for treatment of drug resistant epilepsy in children.

The consortium is investigating the immunomodulatory properties of EVs derived from MSCs in several in vitro and in vivo models. It has been demonstrated by independent research groups that inhibitory effects of MSCs on human leukocytes was mediated by secreted EVs. Subsequently, it was demonstrated by our partners that MSC-derived EVs were responsible for inhibition of B-cell proliferation and differentiation and activation of T-cell apoptosis (Budoni et al., 2013; Del Fattore et al., 2015). These results have been recently confirmed with the CF-MEV-117 drug candidate manufactured by The Cell Factory. Preclinical and clinical study demonstrate that brain inflammation could be responsible for severe epileptic seizures. Pro-inflammatory molecules secreted by the stimulated glial cells are responsible for a status epilepticus. Therefore, immunomodulatory and anti-inflammatory treatment focused on astrocytes and microglia cells are reducing or eliminating symptoms of epilepsy and can prevent a relapse of the disease in the future. The project is investigating anti-inflammatory and anti-epileptic effect of the CF-MEV-117 drug candidate in both an acute phase of epilepsy and preventing development of a chronic disease. In addition, we expect that CF-MEV-117 will demonstrate much broader therapeutic effect in neurology influencing neural cells apoptosis, neurons hyperexcitability, and neurogenesis process leading to faster brain regeneration. This will allow using the MSC-derived EVs in treatment of unmet medical needs e.g. stroke, TBI, spinal cord injury. EVs stability and small size are the key advantages allowing their immediate use in acute injuries and the drug penetration through the blood brain barrier. 

CF-MEV-117 is produced using a proprietary technology developed by The Cell Factory for a large-scale production of ultra-pure EVs, using fully defined, serum-free, xeno-free culture media with no use of animal-derived components and human platelet lysates at any stage of the production process. Production is performed in a closed and scalable stirring bioreactors including a downstream processing based on the integrated sequential filtration system. EVs are continuously secreting by expanded MSCs allowing multiple harvests during one production cycle. This approach significantly reduces the contamination risk, production time, staff, GMP labs use and the cost of goods. Effectively the production of the single EVs dose is now up to 10 times cheaper when comparing to the allogenic MSCs dose equivalent. CF-MEV-117 product is sterilised by filtration during production process what is not possible for any cell therapy products (ATMPs). CF-MEV-117 product has very high batch-to-batch reproducibility. Product analysis is performed using broad range of state-of-the-art techniques i.e. NTA, immunophenotyping, proteomics, among others. Several surface markers have been analysed for CF-MEV-117 product including the tetraspanin transmembrane proteins characteristic for EVs (CD9+, CD63+ and CD81+). Interestingly, CF-MEV-117 EVs do not express HLA-ABC and HLA-DRPQ what increases the drug's safety in human use.

The consortium is fully focused on demonstration of the CF-MEV-117 product's anti-inflammatory and immunosuppressive activity and its mode of action. For that purpose T-cells and B-cells have been isolated from human peripheral blood and the cells were stimulated using anti-CD3/CD28 and CpG, respectively. CF-MEV-117 product has increased the activated T reg proliferation and effectively the T reg / T eff ration. In addition, reduction of the activated B cells proliferation and plasma cell differentiation have been observed in response to CF-MEV-117. This confirms previous results obtained using the research-grade EVs. It is worth stressing that the experiments were performed in parallel with the MSCs used for the CF-MEV-117 production. The results have confirmed the same anti-inflammatory effect of the MSCs and the MSC-derived EVs (CF-MEV-117) on stimulated human leukocytes. The CF-MEV-117 drug's effect was observed in a dose responsive manner. The next step is confirmation of the CF-MEV-117 in in vivo models before the clinical translation.

*EVs including exosomes* are nanometre-size, natural biological particles secreted by different types of cells in vivo and in vitro. They contain proteins, growth factors, mRNA and other molecules responsible for the therapeutic effect of MSCs. In addition, EVs have several advantages over allogenic MSCs e.g.: up to 10-times lower production costs, no risk of uncontrolled proliferation and differentiation, lower risk of immune response and easy and safe delivery into different tissues and organs in vivo. High stability allows for easy transport and storage of the "ready-to-use" products.

*CF-MEV-117 drug candidate: Acute and chronic drug-resistant epilepsy*

The Cell Factory is developing MSC-EVs drug candidate (CF-MEV-117) for treatment of untreatable-yet acute and chronic drug-resistant epilepsy. Epilepsy carries significant detrimental effects on the quality of life and can lead to a secondary brain damage. The disease can have different etiology, including stroke, brain trauma, and neuro-inflammation.

*Epidemiology and market size (CF-MEV-117)*

Epilepsy is one of the most common brain diseases affecting about 1 in 100 children under 17-year old according to CDC. Severity of the seizures is variable and the antiepileptic drugs are effective only in about 2/3 of the patients. CDC estimated annual costs related to epilepsy exceeds 15 billion USD in the United States alone.

It is expected that EVs products will be effective in treatment of other neuroinflammatory-related injuries of central nervous system. Moreover, EVs will be able to target an acute diseases i.e. TBI, brain stroke, spinal cord injury, more effectively when comparing to allogenic MSCs, due to the EV's stability and easier administration at shorter time what is critical for successful therapy. Diseases of central nervous system are among most devastating for patients and their relatives. Neurological disorders are generating a significant additional cost related to hospitalisation, rehabilitation, often eliminate the patients and their relatives from a job market. CDC estimated that annual costs related to epilepsy exceeds 15 billion USD in the United States alone with 50 million patients worldwide (WHO). Cost related to brain stroke in the United States is estimated to 34 billion USD per year (CDA), with 15 million new patients worldwide each year (WHO). Cumulative cost related to traumatic brain injury (TBI) and spinal cost injury in the United States is over 80 billion USD per year (CDA and AANS), with up to 0.5 million new incidents of spinal cord injury and 10 million of TBI per year (WHO). Most of these diseases have no effective therapy yet.

*The consortium* led by Esperite's The Cell Factory is gathering the leading teams in paediatric regenerative medicine, neurology, gastroenterology, immunology and EVs science. The CF-MEV-107 product is developing in collaboration with Professor Maurizio Muraca's team at the Department of Women's and Children's Health at the University of Padova in Italy. The CF-MEV-117 product is developing in collaboration with Professor Federico Vigevano and Dr Alessandra Fierabracci team at Bambino Gesù Children's Hospital in Rome, Italy and with Dr. Annamaria Vezzani at Mario Negri Institute in Milan, Italy.

*Frederic Amar, CEO: "* *The Cell Factory is focused on development, clinical translation and commercialization of the advanced extracellular vesicles (EVs) biologic drugs and autologous stem cell therapies. The Cell Factory goal is to master the development and production of extracellular vesicles drugs in treatment of different indications."*

*ESPERITE Group* , listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and predictive medicine established in 2000.

*The Cell Factory* is a biotech company, a subsidy of the Esperite group, developing highest quality therapeutic tools for affordable regenerative medicine. The Cell Factory led by Dr. Marcin Jurga is focused on development, clinical translation and commercialization of the advanced extracellular vesicles (EVs) biologic drugs and autologous stem cell therapies. The Cell Factory goal is to become a leader in development and production of extracellular vesicles drugs in treatment of different indications i.e. graft versus host disease (GvHD) after solid organ and cell transplantations, arthritis, multiple sclerosis, cystic fibrosis, stroke, traumatic brain and spinal cord injury, newborn encephalopathy, and type 1 diabetes among others.

The Cell Factory focuses on development of the selected EVs drug candidates from a TRL 4 (non-GLP POC) until TRL 6-7 (Clinical phase II). The Cell Factory is looking for partners and investors who are interested in a rapidly growing, disruptive technology of EVs biological drugs. We are looking for different collaboration models including out-licencing, technology transfer and joint venture product development and dilutive investments.

The Cell Factory owns the full rights of a broad international patent family enabling MSC-derived extracellular vesicles (EVs) use in treatment of autoimmune, chronic and acute inflammatory diseases. The patents have been already granted in Europe and recently in China. The Cell Factory is developing the EVs biologic drug products for multiple indications in immunology, neurology and gastroenterology. The leading products are CF-MEV-107 for treatment of Crohn's disease (drug resistant perianal fistulae) and CF-MEV-117 for treatment of drug resistant epilepsy in children. The CF-MEV-107 product is ready for clinical translation and the consortium of leading academic and clinical teams sponsored by The Cell Factory is preparing the CF-MEV-107 product for first in man clinical translation in 2017.

To learn more about ESPERITE Group, or to book an interview with CEO Frederic Amar: +31 575 548 998 -  ir@esperite.com  or visit the websites at www.esperite.com, www.cell-factory.com, www.cryo-save.com and www.genoma.com.

PR EV epilepsy product development
--------------------This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Esperite N.V. via GlobeNewswire

HUG#2102152 Reported by GlobeNewswire 6 minutes ago.

3 African Runners Will Try to Break Marathon Barrier

0
0
Three elite runners from East Africa will try Saturday to reach one of track and field's most elusive goals: the sub-two-hour marathon. Eliud Kipchoge of Kenya, Lelisa Desisa of Ethiopia and Zersenay Tadese of Eritrea will run on a flat, closed 2.4-kilometer course in Monza, Italy, chosen for its optimal altitude and track conditions for running.    The race is sponsored by sportswear manufacturer Nike Inc., which recently launched what it called a "moonshot"... Reported by VOA News 12 hours ago.

BandwidthX Opens New European Office

0
0
The new office allows BandwidthX to accelerate growth in sales and customer support

Carlsbad, CA (PRWEB) May 05, 2017

BandwidthX, the mobile data market, today announces the opening of its Barcelona office. The company has now expanded its presence to Europe to accommodate rapid growth and to better service its existing customers. The new BandwidthX office is located in the heart of the Eixample district in Barcelona, Spain.

The company’s European operations and the new office will be led by Giorgio Miano, the Vice Present of EMEA. Previously Mr. Miano held several executives roles, including VP & Managing Director Europe and SVP Caribbean and Latin America at Syniverse where he worked for 12 years from 2004 to 2016. Prior to Syniverse, he held various positions at Wind Telecommunications in Italy from 2000 to 2003 and at ExxonMobil in Italy from 1996 to 1998. Mr. Miano holds an Advanced Degree in Business and Economics from the University of La Sapienza of Rome and a Master’s Degree in Cooperation and International Development from the University of Pavia in Italy.

BandwidthX operates an advanced connection management service and a cloud-based market, BxMarket, where both Mobile Operators and Network Service Providers can define their value for data capacity in real time and are automatically matched when their values align. The business-to-business solution enables Mobile Operators to precisely meet data demand by automatically accessing available Wi-Fi and buying unused data capacity from Network Service Providers. The company has solved the two key issues in utilizing excess capacity in mobile data networks: making sure that every automated connection improves the end user’s experience and providing the mobile operator effective control of exactly when and how data capacity from various sources is used. BxMarket brings savings for Mobile Operators, new revenue streams for Network Service Providers, and better service for end-users.

“We are really pleased to begin our Europe-based operations and to have Giorgio Miano head up the new expansion. The decision to establish our presence in Europe was a logical step in our business strategy,” says Pertti Visuri, CEO of BandwidthX, “It improves our ability to serve current customers and to bring the benefits of our service to additional mobile service providers and network operators in this important market.”

For further information about BandwidthX and its solution, visit http://bandwidthx.com or follow @BandwidthX on Twitter.

Ends

About BandwidthX

BandwidthX operates an advanced connection management service and a cloud-based market where both Mobile Operators and Network Service Providers can define their value for data capacity in real time and are automatically matched when their values align. BxMarket gives the Mobile Operators incremental data capacity at lower cost, while allowing the Network Service Providers to profit from new revenue streams from their underutilized data networks. With this new form of micro-commerce, everyone in the mobile data ecosystem wins: from Mobile Operators and Network Service Providers to equipment and software vendors, aggregators and financial clearing companies and, of course, the end user of the device. Learn more about BandwidthX at http://www.bandwidthx.com. Reported by PRWeb 10 hours ago.
Viewing all 40166 articles
Browse latest View live




Latest Images